IM Cannabis
Importer, brand manager and pharmacy distributor of medical cannabis in Israel and Germany.
Something off on this page? Send us feedback.
Profile
Imports, brands and distributes medical cannabis in Israel and Germany, selling mostly flower through pharmacies, retail and online channels. The German Adjupharm platform handles the regulated import-to-pharmacy chain and supplies most continuing revenue.
Imports medical cannabis from licensed suppliers in Israel, markets IMC, Roma, WAGNERS, BLKMKT, LOT420, PICO, Flower and TOKEN, and reaches patients through pharmacies, owned retail stores and online channels. Dried flower is the central product, alongside selected oils and extracts.
Runs the German operation through Adjupharm, which imports, processes and distributes products to licensed pharmacies. Its logistics center handles storage, repackaging, stability testing, batch release and distribution. Germany provides most continuing revenue; Israel supplies the remainder, and no U.S. cannabis activities are reported.
Depends on pharmacy, narcotics, wholesale, import and other regulated licenses, EU-GMP suppliers, contracted packagers and international logistics. The pending European-asset sale to an entity controlled by the CEO is non-binding.
Company facts
Categories
Key statistics
Year to date −92.4% · Average volume (30d) 164.5K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | — | −$0.34 | — | — | $5.5M | — | −6.15% |
| May 13, 2026Q1 FY26 | — | −$0.28 | — | — | $4.5M | — | −3.19% |
| Mar 30, 2026Q4 FY25 | $0.09 | −$0.86 | −1,100.5% | $15.7M | $8.2M | −47.7% | −9.31% |
| Nov 13, 2025Q3 FY25 | −$0.02 | −$0.54 | −2,234.6% | $14.3M | $9.9M | −30.4% | −5.34% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $9.1M | $10.0M | $8.1M | $6.2M | $5.6M | |
| Gross profit | $2.5M | $2.5M | $2.0M | $42.3K | $1.0M | $1.1M | |
| Operating income | $113.7K | −$251.8K | −$3.0M | −$2.0M | −$1.2M | −$1.5M | |
| Net income | $197.8K | −$222.3K | −$2.6M | −$3.9M | −$1.6M | −$3.2M | |
| Diluted EPS | $0.06 | −$0.07 | −$0.54 | −$0.92 | −$8.20 | −$10.36 | |
| Gross margin | 27.6% | 27.0% | 19.7% | 0.5% | 16.3% | 19.8% | |
| Operating margin | 1.3% | -2.8% | -30.0% | -25.1% | -19.3% | -27.5% |
Fiscal years (4-quarter sums)FY21 $34.5M · FY22 $47.1M · FY23 $35.6M · FY24 $38.9M · FY25 $36.2M
Revenue by product · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $1.3M · Total debt $10.0M · Total assets $17.8M · Shareholders' equity −$4.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 603.9K · Float 186.5K · 30.9% free float
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Tilray Brands
German medical-cannabis cultivation and pharmacy distribution.
- Aurora Cannabis
German medical-cannabis flower and EU-GMP supply.
- InterCure
Israeli medical-cannabis brands, retail pharmacies, and German access.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| IM Cannabis | $3.58 | +4.99% | $2.1M | — | — | 0.7 | −41.2% |
| Tilray Brands | $4.59 | +0.17% | $513.3M | — | — | 0.4 | +25.5% |
| Aurora Cannabis | $4.01 | +0.25% | $248.4M | — | — | 1.2 | −26.5% |
| InterCure | $5.78 | +1.05% | $68.5M | — | — | 0.8 | — |
| Median | — | — | 0.8 | −0.5% |